GSA Capital Partners LLP Purchases 353,384 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

GSA Capital Partners LLP raised its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 138.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 608,585 shares of the company's stock after acquiring an additional 353,384 shares during the period. GSA Capital Partners LLP owned about 0.86% of Zentalis Pharmaceuticals worth $2,240,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Decheng Capital LLC boosted its stake in Zentalis Pharmaceuticals by 46.2% in the second quarter. Decheng Capital LLC now owns 3,070,442 shares of the company's stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Zentalis Pharmaceuticals by 20.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company's stock valued at $54,999,000 after purchasing an additional 585,644 shares during the period. Renaissance Technologies LLC increased its position in Zentalis Pharmaceuticals by 152.6% in the second quarter. Renaissance Technologies LLC now owns 661,682 shares of the company's stock worth $2,706,000 after buying an additional 399,745 shares during the last quarter. Opaleye Management Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at $3,152,000. Finally, XTX Topco Ltd lifted its position in shares of Zentalis Pharmaceuticals by 1,581.9% during the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company's stock valued at $730,000 after buying an additional 167,854 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on ZNTL shares. Oppenheimer reaffirmed an "outperform" rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Wedbush upgraded Zentalis Pharmaceuticals from an "underperform" rating to a "neutral" rating and set a $4.00 price target for the company in a research report on Monday, August 12th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $10.25.

Zentalis Pharmaceuticals Trading Down 6.5 %

Shares of Zentalis Pharmaceuticals stock traded down $0.26 on Tuesday, hitting $3.77. 247,450 shares of the company traded hands, compared to its average volume of 1,321,303. Zentalis Pharmaceuticals, Inc. has a 12-month low of $2.66 and a 12-month high of $18.07. The company has a market cap of $268.08 million, a P/E ratio of -1.48 and a beta of 1.74. The firm's 50-day simple moving average is $3.38 and its 200 day simple moving average is $5.59.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Friday, August 9th. The company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.40). During the same quarter last year, the firm posted ($1.85) earnings per share. Analysts predict that Zentalis Pharmaceuticals, Inc. will post -3.02 earnings per share for the current year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.